Last reviewed · How we verify
microcrystalline cellulose capsules
microcrystalline cellulose capsules is a Small molecule drug developed by Neuralstem Inc.. It is currently in Phase 1 development.
Microcrystalline cellulose capsules are used as a placebo in clinical trials for various conditions, including Parkinson's disease, muscle damage, arthritis, and delirium. The exact mechanism of microcrystalline cellulose is unknown, as indicated by ChEMBL.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | microcrystalline cellulose capsules |
|---|---|
| Sponsor | Neuralstem Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Effect of Oral Microbiota on MDRO Decolonization (PHASE1, PHASE2)
- First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics (PHASE1)
- VE303 for Prevention of Recurrent Clostridioides Difficile Infection (PHASE3)
- Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants (PHASE2, PHASE3)
- Effects of P24 on Postprandial Aminoacidemia (NA)
- A Study to Assess the Effect of the Bio-K+ Probiotic Capsules (VL-BK-02) in Adults With Functional Constipation (NA)
- The Effects of High-dose Vitamin B6 on Depression and Anxiety Symptoms (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- microcrystalline cellulose capsules CI brief — competitive landscape report
- microcrystalline cellulose capsules updates RSS · CI watch RSS
- Neuralstem Inc. portfolio CI
Frequently asked questions about microcrystalline cellulose capsules
What is microcrystalline cellulose capsules?
Who makes microcrystalline cellulose capsules?
What development phase is microcrystalline cellulose capsules in?
Related
- Manufacturer: Neuralstem Inc. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing